GliaPharm is a Swiss biotechnology company that develops treatments for neurological and psychiatric disorders.
GliaPharm's innovative therapeutic approach is to target glial cells, the 'support cells' of neurons, to sustain and enhance brain metabolism in pathological conditions. Our vision is to become a leading biotechnology company with a focus on glia-mediated pathways as agents for neuroprotection and maintenance of cognitive functions.
GliaPharm est une entreprise suisse de biotechnologies active dans le développement de traitements de maladies neurologiques et psychiatriques.
L'approche thérapeutique innovante de GliaPharm est de cibler les cellules gliales, ou 'cellules de soutien' des neurones, afin de soutenir et améliorer le métabolisme cérébral dans certaines conditions pathologiques. Notre vision est de devenir leader dans le développement d'agents ciblant les cellules gliales qui agissent comme neuroprotecteurs et maintiennent les fonctions cognitives.
JANUARY 2019
We made it to the @hellotmrc Global Finals of #HTChallenge! From 4,500 applications we have been named one of the 7 Industrial Biotech track Finalists competing to win at the #HTSummit! Come hear us pitch in Paris on March 14-15.
SEPTEMBER 2017
GliaPharm receives the Cydan Award of the MassChallenge startup Accelerator program in Boston, 2017
MAY 2017
GliaPharm has been selected as a Finalist to the MassChallenge Switzerland 2017 startup contest